Achieve Life Sciences

Achieve Life Sciences has appointed Jeff Farrow and Dr. Reid Waldman to the board effective Thursday. Farrow will chair the audit committee and serve on the nominating and corporate governance committee; Waldman will chair the compensation committee and serve on the trade committee. Both will receive the standard external director compensation (pro rata annual base cash compensation of $40,000, plus additional cash payments for committee service) and will each be granted an option on 47,250 common shares that vests monthly over three years; the appointments were reported in an 8‑K filed with the SEC. The company recently saw a strong share price rise (last week +16%, YTD +36%), reported Q1 EPS of -$0.19 (better than expected), and presented positive long-term safety data for Cytisiniclin from the ORCA-OL study. » Mais em de.investing.com

Achieve Life Sciences reported Q1 2026 EPS of -$0.19, a positive surprise versus the consensus estimate of -$0.43. The company secured $180 million in fresh capital and highlighted promising clinical data for Cytisiniclin. Management plans to resubmit the NDA in Q4 2026 with a target launch in the first half of 2027, but notes risks from production changes and regulatory delays. » Mais em de.investing.com

Achieve Life Sciences appoints three former Verona executives to leadership roles (Christopher Martin to the board, Mark Zappia as senior VP commercial and Jim Willis as VP sales) to prepare for the potential market launch of Cytisiniclin for smoking cessation. Earlier, Andrew D. Goldberg was named CEO and the company secured up to $354 million in financing, including a $180 million upfront payment and up to $174 million in milestone payments contingent on FDA approval. The FDA set the PDUFA date for the new drug application as June 20, 2026; Achieve has submitted phase 3 data and additional studies. The stock is trading near its 52-week high and has returned 125% year-to-date; analysts see price targets between $10 and $20 but warn of possible overvaluation. » Mais em de.investing.com